Alkermes Plc (ALKS)vsViatris Inc (VTRS)
ALKS
Alkermes Plc
$45.97
-0.30%
HEALTHCARE · Cap: $7.63B
VTRS
Viatris Inc
$16.51
+0.79%
HEALTHCARE · Cap: $19.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 784% more annual revenue ($14.74B vs $1.67B). ALKS leads profitability with a 4.0% profit margin vs -2.8%. VTRS appears more attractively valued with a PEG of 1.05. VTRS earns a higher WallStSmart Score of 48/100 (D+).
ALKS
Hold46
out of 100
Grade: D+
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+54.4%
Fair Value
$76.49
Current Price
$45.97
$30.52 discount
Margin of Safety
-85.0%
Fair Value
$8.72
Current Price
$16.51
$7.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 27.0% year-over-year
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
4.0% margin — thin
Premium valuation, high expectations priced in
Earnings declined 99.4%
4.9% revenue growth
ROE of -2.9% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ALKS
The strongest argument for ALKS centers on Revenue Growth. Revenue growth of 27.0% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.
Bear Case : ALKS
The primary concerns for ALKS are PEG Ratio, Profit Margin, P/E Ratio. A P/E of 119.7x leaves little room for execution misses. Thin 4.0% margins leave little buffer for downturns.
Bear Case : VTRS
The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.
Key Dynamics to Monitor
ALKS profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.88 — expect wider price swings.
ALKS is growing revenue faster at 27.0% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Bottom Line
VTRS scores higher overall (48/100 vs 46/100). ALKS offers better value entry with a 54.4% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alkermes Plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
Visit Website →Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?